EGFR Cancer Research Results

EGFR, Epidermal Growth Factor Receptor: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-Driver
Type: Oncogene
EGFR (Epidermal growth factor receptor), which belongs to the tyrosine kinase receptor family (RTKs)
Epidermal Growth Factor Receptor (EGFR) is a cell surface protein that plays a crucial role in the regulation of cell growth, survival, proliferation, and differentiation. It is part of the ErbB family of receptors and is activated by binding to its ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α).

-plays a crucial role in regulating cell growth and division.

Many cancers exhibit overexpression of EGFR, which can lead to enhanced signaling and contribute to tumor growth and survival. This overexpression is often associated with aggressive tumor behavior and poor prognosis.
Lung, Lung Cancer: Click to Expand ⟱
Lung CSC (Cancer Stem Cells) markers (CD133, CD44, ALDHA1, Nanog and Oct4)
Scientific Papers found: Click to Expand⟱
231- AL,    EGFR_Protein_for_Lung_Cancer_Therapy">Molecular Docking Studies with Garlic Phytochemical Constituents to Inhibit the Human EGFR Protein for Lung Cancer Therapy
- Analysis, Lung, NA
EGFR↓, ROS↑,
5729- BF,    Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling
- in-vitro, Lung, NA
TumCCA↑, Apoptosis↑, TumCG↓, EGFR↓, PI3K↓, Akt↓, mTOR↓, P70S6K↓,
5728- BF,    Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action
- in-vitro, Lung, A549
TumCP↓, Apoptosis↑, TumCCA↑, Bcl-2↝, BAX↝, Cyt‑c↝, Casp3↝, PARP↝, P21↝, cycD1/CCND1↝, COX2↝, p‑VEGFR2↓, EGFR↓, Akt↓, NF-kB↓, p44↓,
5691- BRU,    Brusatol Inhibits Proliferation, Migration, and Invasion of Nonsmall Cell Lung Cancer PC-9 Cells
- in-vitro, Lung, PC9 - in-vitro, Lung, H1975
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EGFR↓, β-catenin/ZEB1↓, Akt↓, STAT3↓, TumMeta↓, ChemoSen↑, NRF2↓, Akt↓, mTOR↓,
5699- BRU,  BJ,    Identification of the Brucea javanica Constituent Brusatol as a EGFR-Tyrosine Kinase Inhibitor in a Cell-Free Assay
- in-vitro, Lung, A549
EGFR↓, ChemoSen↑, NRF2↓, STAT3↓, PI3K↓, Akt↓, mTOR↓, ROCK1↓, Hif1a↓,
2979- CUR,  GB,    Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
- in-vitro, Lung, H157 - in-vitro, Lung, H1299
EGFR↓, Sp1/3/4↓, ERK↓, MEK↓, Akt↓, S6K↓,
1113- FIS,    Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, MMP2↓, CD44↓, CD133↓, β-catenin/ZEB1↓, NF-kB↓, EGFR↓, STAT3↓, CSCs↓,
997- GA,    The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H292 - in-vitro, Nor, HUVECs
PD-L1↓, p‑EGFR↓, p‑PI3K↓, p‑Akt↓, P53↑, miR-34a↑, *toxicity↓,
2874- HNK,    Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6‐mediated matrix metalloproteinase 9
- in-vitro, Lung, H1299
MMP9↓, α-tubulin↑, TumCI↓, HDAC6↓, HSP90↓, TumCMig↓, EGFR↓,
2876- HNK,    Honokiol from Magnolia spp. induces G1 arrest via disruption of EGFR stability through repressing HDAC6 deacetylated Hsp90 function in lung cancer cells
- in-vitro, Lung, A549 - in-vitro, Lung, H23 - in-vitro, Lung, HCC827
EGFR↓, HSP90↓,
2897- HNK,    Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells
- in-vitro, Lung, PC9 - in-vitro, Lung, A549
TumCP↓, Apoptosis↑, EGFR↓, PI3K↓, Akt↓, STAT3↓, TumCI↓, TNF-α↑, NF-kB↓, VEGF↓, MMP9↓, COX2↓,
2940- PL,    Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors
- in-vitro, PC, PANC1 - in-vitro, Lung, A549 - in-vitro, Kidney, 786-O - in-vitro, BC, SkBr3
ROS↑, TumCP↓, Apoptosis↑, eff↓, Sp1/3/4↓, cycD1/CCND1↓, survivin↓, cMyc↓, EGFR↓, cMET↓,
2440- RES,    Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway
- in-vitro, Lung, H460 - in-vivo, Lung, NA - in-vitro, Lung, H1650 - in-vitro, Lung, HCC827
AntiTum↑, Glycolysis↓, HK2↓, EGFR↓, Akt↓, ERK↓, GlucoseCon↓, lactateProd↓, TumCG↓, Ki-67↓,
1460- SFN,    High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells
- in-vitro, Lung, NA
ROS↑, EGFR↓, eff↓, TumCCA↑, γH2AX↑, DNAdam↑, eff↓,
2010- SK,    Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway
- in-vitro, Lung, H1975 - in-vitro, Lung, H1650 - in-vitro, Nor, CCD19
EGFR↓, selectivity↑, Casp↑, PARP↑, Apoptosis↑, ROS↑, eff↓, selectivity↑,

Showing Research Papers: 1 to 15 of 15

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 15

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

NRF2↓, 2,   ROS↑, 4,  

Mitochondria & Bioenergetics ⓘ

MEK↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,   S6K↓, 1,  

Cell Death ⓘ

Akt↓, 8,   p‑Akt↓, 1,   Apoptosis↑, 6,   BAX↝, 1,   Bcl-2↝, 1,   Casp↑, 1,   Casp3↝, 1,   Cyt‑c↝, 1,   survivin↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 2,  

Protein Folding & ER Stress ⓘ

HSP90↓, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↑, 1,   PARP↑, 1,   PARP↝, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   cycD1/CCND1↝, 1,   P21↝, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD44↓, 1,   cMET↓, 1,   CSCs↓, 1,   EMT↓, 1,   ERK↓, 2,   HDAC6↓, 1,   miR-34a↑, 1,   mTOR↓, 3,   P70S6K↓, 1,   PI3K↓, 3,   p‑PI3K↓, 1,   STAT3↓, 4,   TumCG↓, 2,  

Migration ⓘ

E-cadherin↑, 1,   Ki-67↓, 1,   MMP2↓, 1,   MMP9↓, 2,   N-cadherin↓, 1,   p44↓, 1,   ROCK1↓, 1,   TumCI↓, 4,   TumCMig↓, 3,   TumCP↓, 4,   TumMeta↓, 1,   Vim↓, 1,   ZO-1↑, 1,   α-tubulin↑, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 14,   p‑EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 1,   p‑VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   COX2↝, 1,   NF-kB↓, 3,   PD-L1↓, 1,   TNF-α↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,   eff↓, 4,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

EGFR↓, 14,   p‑EGFR↓, 1,   Ki-67↓, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 76

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: EGFR, Epidermal Growth Factor Receptor
3 Honokiol
2 Bufalin/Huachansu
2 brusatol
1 Allicin (mainly Garlic)
1 Brucea javanica
1 Curcumin
1 gefitinib, erlotinib
1 Fisetin
1 Gallic acid
1 Piperlongumine
1 Resveratrol
1 Sulforaphane (mainly Broccoli)
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:15  Cells:%  prod#:%  Target#:94  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page